Literature DB >> 35610351

Generation of human A9 dopaminergic pacemakers from induced pluripotent stem cells.

Hong Li1, Houbo Jiang1,2, Hanqin Li1, Li Li1, Zhen Yan1,2, Jian Feng3,4.   

Abstract

The degeneration of nigral (A9) dopaminergic (DA) neurons causes motor symptoms in Parkinson's disease (PD). We use small-molecule compounds to direct the differentiation of human induced pluripotent stem cells (iPSCs) to A9 DA neurons that share many important properties with their in vivo counterparts. The method generates a large percentage of TH+ neurons that express appropriate A9 markers, such as GIRK2 and ALDH1A1, but mostly not the A10 marker CALBINDIN. Functionally, they exhibit autonomous pacemaking based on L-type voltage-dependent Ca2+ channels and show autoreceptor-dependent regulation of dopamine release. When transplanted in the striatum of 6-OHDA-lesioned athymic rats, the human A9 DA neurons manifest robust survival and axon outgrowth, and ameliorate motor deficits in the rat PD model. The ability to generate patient-specific A9 DA autonomous pacemakers will significantly improve PD research and facilitate the development of disease-modifying therapies.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35610351     DOI: 10.1038/s41380-022-01628-1

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


  55 in total

1.  Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum.

Authors:  Wakoto Matsuda; Takahiro Furuta; Kouichi C Nakamura; Hiroyuki Hioki; Fumino Fujiyama; Ryohachi Arai; Takeshi Kaneko
Journal:  J Neurosci       Date:  2009-01-14       Impact factor: 6.167

2.  Discovery of high-frequency deep brain stimulation for treatment of Parkinson disease: 2014 Lasker Award.

Authors:  Mahlon R DeLong; Alim-Louis Benabid
Journal:  JAMA       Date:  2014-09-17       Impact factor: 56.272

Review 3.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

4.  Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections.

Authors:  Lachlan Thompson; Perrine Barraud; Elin Andersson; Deniz Kirik; Anders Björklund
Journal:  J Neurosci       Date:  2005-07-06       Impact factor: 6.167

5.  Subdivisions of the dopamine-containing A8-A9-A10 complex identified by their differential mesostriatal innervation of striosomes and extrastriosomal matrix.

Authors:  J Jimenez-Castellanos; A M Graybiel
Journal:  Neuroscience       Date:  1987-10       Impact factor: 3.590

6.  Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat.

Authors:  D C German; K F Manaye
Journal:  J Comp Neurol       Date:  1993-05-15       Impact factor: 3.215

7.  Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans.

Authors:  D A McRitchie; C D Hardman; G M Halliday
Journal:  J Comp Neurol       Date:  1996-01-01       Impact factor: 3.215

8.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

Authors:  P Damier; E C Hirsch; Y Agid; A M Graybiel
Journal:  Brain       Date:  1999-08       Impact factor: 13.501

9.  The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease.

Authors:  Shane Grealish; Marie E Jönsson; Meng Li; Deniz Kirik; Anders Björklund; Lachlan H Thompson
Journal:  Brain       Date:  2010-01-31       Impact factor: 13.501

10.  The control of firing pattern in nigral dopamine neurons: single spike firing.

Authors:  A A Grace; B S Bunney
Journal:  J Neurosci       Date:  1984-11       Impact factor: 6.167

View more
  1 in total

1.  Combination therapy using GDNF and cell transplant in Parkinson's disease.

Authors:  Bin Xiao; Su-Chun Zhang; Eng-King Tan
Journal:  Mol Neurodegener       Date:  2022-07-16       Impact factor: 18.879

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.